This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (54)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Herbert Y. Meltzer, MD

Arch Gen Psychiatry. 1989;46(7):672.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Clozapine has been shown to be superior to chlorpromazine and haloperidol in treatment-resistant schizophrenic patients.¹ It has not yet been approved for use in the United States, but it is available in over 100 sites on a compassionate need basis. Well over 500 patients are currently receiving it in this country. The duration of an adequate trial is, therefore, of critical importance. In the study by Kane et al,¹ only 30% of patients had responded within 6 weeks of starting drug therapy. Other studies or commentaries on the use of clozapine in treatment-resistant patients have not addressed this issue.^2-5

We have now administered clozapine on an open basis to 51 schizophrenic patients who are comparable to the group studied by Kane et al.^1,6 Sixteen (31.4%) of the 51 patients responded within 6 weeks with a 20% or more decrease in the . . . [Full Text PDF of this Article]

Author Affiliations
Department of Psychiatry Case Western Reserve University 2040 Abington Rd Cleveland, OH 44106

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?